Detalles de la búsqueda
1.
Trop-2 expression and the tumor immune microenvironment in cervical cancer.
Gynecol Oncol
; 187: 51-57, 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38723340
2.
A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
Jpn J Clin Oncol
; 54(4): 424-433, 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38251744
3.
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.
BMC Cancer
; 22(1): 869, 2022 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35945547
4.
Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Int J Gynecol Cancer
; 27(8): 1666-1674, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28786875
5.
[â ¢. Current Status and Future Development of Anti-Cancer Drugs in Rare Gynecologic Cancers-The Rise of Anti-HER2 Therapy].
Gan To Kagaku Ryoho
; 48(2): 200-205, 2021 Feb.
Artículo
en Japonés
| MEDLINE | ID: mdl-33597359
6.
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Anticancer Res
; 43(3): 1265-1272, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36854492
7.
Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.
Hum Cell
; 30(2): 140-148, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27889902
Resultados
1 -
7
de 7
1
Próxima >
>>